目的 探討復(fù)方斑蝥膠囊聯(lián)合TAC方案治療三陰性乳腺癌的療效。方法 選取2020年4月—2023年3月在東臺(tái)市中醫(yī)院就診的100例三陰性乳腺癌患者，根據(jù)隨機(jī)數(shù)字表法將100例患者分為對(duì)照組（50例）和治療組（50例）。對(duì)照組給予TAC方案治療，第1天靜脈注射多西他賽注射液75 mg/m²、靜脈滴注注射用環(huán)磷酰胺600 mg/m²、靜脈注射注射用鹽酸表柔比星80 mg/m²。治療組在對(duì)照組基礎(chǔ)上口服復(fù)方斑蝥膠囊，3粒/次，2次/d。以21 d為1個(gè)化療周期，兩組在持續(xù)治療6個(gè)周期后分析療效。比較兩組的臨床療效、生活質(zhì)量、淋巴細(xì)胞相關(guān)指標(biāo)、腫瘤標(biāo)志物、血清指標(biāo)和不良反應(yīng)的情況。結(jié)果 治療后，治療組的總有效率（94.00%）高于對(duì)照組（80.00%），組間比較差異顯著（P＜0.05）。治療后，兩組的乳腺癌生活質(zhì)量量表（QLSBC）評(píng)分低于治療前（P＜0.05），且治療組QLSBC評(píng)分低于對(duì)照組（P＜0.05）。治療后，治療組的CD8⁺比治療前小，LMR、CD4⁺、CD4⁺/CD8⁺比治療前大（P＜0.05）；治療組的CD8⁺比對(duì)照組小，LMR、CD4⁺、CD4⁺/CD8⁺比對(duì)照組大（P＜0.05）。治療后，兩組的血清糖蛋白抗原（CA153）、癌胚抗原（CEA）水平均比治療前低（P＜0.05）；治療組血清CA153、CEA水平比對(duì)照組低（P＜0.05）。治療后，兩組的血清脂聯(lián)素（ADP）水平高于治療前，血清白細(xì)胞介素-8（IL-8）水平低于治療前（P＜0.05）；治療組的血清ADP水平高于對(duì)照組，血清IL-8水平低于對(duì)照組（P＜0.05）。治療期間，治療組的不良反應(yīng)發(fā)生率比對(duì)照組低，組間比較差異顯著（P＜0.05）。結(jié)論 復(fù)方斑蝥膠囊聯(lián)合TAC方案有助于提高三陰性乳腺癌的療效，有助于改善患者的免疫功能和生活質(zhì)量，降低腫瘤標(biāo)志物的水平和藥物不良反應(yīng)的發(fā)生。

Objective To investigate the efficacy of Compound Banmao Capsules combined with TAC regimen in treatment of triple negative breast cancer. Methods Patients (100 cases) with triple negative breast cancer in Dongtai Hospital of TCM from April 2020 to March 2023 were divided into control and treatment groups according to the random number table method, and each group had 50 cases. Patients in the control group was treated with TAC regimen. On the first day, patients in the control group received intravenous injection of 75 mg/m² of Docetaxel Injection, intravenous drip of 600 mg/m² of Cyclophosphamide for injection, and intravenous injection of 80 mg/m² of Epirubicin Hydrochloride Injection. Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of the control group, 3 grains/time, twice daily. One chemotherapy cycle had 21 days, and the efficacy of the two groups was analyzed after continuous treatment for 6 cycles.The clinical efficacies, Quality of life, lymphocyte related indicators, tumor markers and serum indicators, and adverse reactions in two groups were compared. Results After treatment, the total effective rate of the treatment group (94.00%) was higher than that of the control group (80.00%), and the difference between groups was significant (P＜0.05). After treatment, the QLSBC score of breast cancer in two groups was lower than that before treatment (P＜0.05), and the QLSBC score in the treatment group was lower than that in the control group (P＜0.05). After treatment, CD8⁺ in the treatment group was smaller than before treatment, but LMR, CD4⁺, CD4⁺/CD8⁺ were larger than those before treatment (P＜0.05). CD8⁺ in the treatment group was smaller than that in the control group, while LMR, CD4⁺, CD4⁺/CD8⁺ were larger than those in the control group (P＜ 0.05). After treatment, the serum levels of CA153 and CEA in two groups were lower than those before treatment (P＜0.05). The serum levels of CA153 and CEA in the treatment group were lower than those in the control group (P＜0.05). After treatment, the serum levels of ADP in two groups were higher than those before treatment, but the serum levels of IL-8 were lower than before treatment (P＜0.05). The serum level of ADP in the treatment group was higher than that in the control group, but the serum level of IL-8 was lower than that in the control group (P＜0.05). During the treatment period, the incidence of adverse reactions in the treatment group was lower than that in the control group, and there was a significant difference between the groups (P＜0.05). Conclusion Compound Banmao Capsules combined with TAC regimen is helpful to improve the efficacy of triple negative breast cancer, improve the immune function and quality of life of patients, reduce the level of tumor markers, and reduce the occurrence of adverse drug reactions.

R979.1

鹽城市科技項(xiàng)目（YCBE202235）